BNTC — Benitec Biopharma Income Statement
0.000.00%
Last trade - 00:00- $405.67m
- $311.19m
- 43
- 20
- 90
- 50
Annual income statement for Benitec Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.059 | 0.073 | 0.075 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -0.064 | 0.064 | 0.075 | 0.108 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13.7 | 17.9 | 19.2 | 22.5 | 41 |
| Operating Profit | -13.6 | -17.9 | -19.1 | -22.5 | -41 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.9 | -18.2 | -19.6 | -21.8 | -37.9 |
| Net Income After Taxes | -13.9 | -18.2 | -19.6 | -21.8 | -37.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.9 | -18.2 | -19.6 | -21.8 | -37.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.9 | -18.2 | -19.6 | -22.4 | -37.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -54.9 | -37.9 | -14.1 | -5.51 | -1.07 |